[go: up one dir, main page]

WO2008134923A1 - A preparation method of thiol derivative as side chain intermediate for synthesis of carbapenem derivative - Google Patents

A preparation method of thiol derivative as side chain intermediate for synthesis of carbapenem derivative Download PDF

Info

Publication number
WO2008134923A1
WO2008134923A1 PCT/CN2008/000814 CN2008000814W WO2008134923A1 WO 2008134923 A1 WO2008134923 A1 WO 2008134923A1 CN 2008000814 W CN2008000814 W CN 2008000814W WO 2008134923 A1 WO2008134923 A1 WO 2008134923A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
derivative
branched
chain intermediate
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2008/000814
Other languages
French (fr)
Chinese (zh)
Inventor
Jianping Cai
Enhai Fan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZHEJIANG NEXCHEM PHARMACEUTICAL CO Ltd
Original Assignee
ZHEJIANG NEXCHEM PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZHEJIANG NEXCHEM PHARMACEUTICAL CO Ltd filed Critical ZHEJIANG NEXCHEM PHARMACEUTICAL CO Ltd
Publication of WO2008134923A1 publication Critical patent/WO2008134923A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms

Definitions

  • the present invention relates to the field of organic chemistry and medicinal chemistry, and in particular, to a method for preparing a thiol derivative of a medicinal branched intermediate of piran. Background technique
  • Peron (carbampenal) drugs such as imipenem, meropenem and biapenem have good antibacterial activity against many resistant bacteria, especially for B-type enzymes.
  • (2S, 4S)-Substituted carbamoyl-4-mercapto- 1-(N-substituted) pyrrolizole (i) is an important branched intermediate of piranol drugs such as meropenem.
  • a lower decyloxycarbonyl group, a halogenated decyloxycarbonyl group, a fluorenyloxycarbonyl group having a aromatic diameter, and a trimethylsilyl group, and R 4 and R 5 represent the same or different hospitals containing d-Cs carbon atoms.
  • can be tert-butoxycarbonyl, 2, 2, 2-trichloroethoxycarbonyl, 2-bromoethoxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, trimethyl A silyl group or a tert-butyldimethylsilyl group; and R 2 may be an ethoxycarbonyl group, a tert-butoxycarbonyl group, an isopropoxycarbonyl group, a methanesulfonyl group or a p-toluenesulfonyl group.
  • R 4 and R 5 may be the same or different and include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, propenyl, butenyl, phenyl, substituted phenyl, pyridyl, 2 Pyridinemethyl, 3-pyridylmethyl, 4-pyridylmethyl.
  • the first method is to use t ns-4-hydroxy-L-proline as the raw material, protected by the amino group on the pyrrole ring, the 2-position carboxyl group is protected to form an ester, the 4-position hydroxyl group is substituted to obtain a vapor, and then the second position is hydrolyzed.
  • the carboxylic acid, the amidation, and the 4-position hydrolysis are carried out in a total of 6 steps to obtain the compound (i), and the reaction route is as follows:
  • Another method is to use trans- 4-hydroxy-L-proline as a raw material, protected by an amino group on a pyrrole ring, and the 2-position carboxyl group is directly reacted with a secondary amine to obtain an amide, and then substituted at the 4-position to obtain a compound (i). ), its synthetic route is as follows:
  • Patent W09902513 mentions another route which uses amino-protected trans-4-hydroxy-L-proline as a raw material, is protected by a 2-carboxyl group, a 4-hydroxyl group, is ring-closed, and is ring-opened to obtain a compound (i).
  • the synthetic route is as follows:
  • the object of the present invention is to provide a preparation method of a perylene-based drug branched-chain intermediate-thiol derivative, and the synthetic route of the preparation method is as shown in formula 4:
  • a method for preparing a peronal drug branched-chain intermediate monothiol alcohol derivative characterized in that the method comprises the following steps:
  • the compound (vi) is hydrolyzed under basic conditions to obtain a thiol derivative (i) of a perindanic branched intermediate.
  • a thiol derivative (i) of a perindanic branched intermediate represents an acyl compound.
  • the compound (iii) and the compound (iv) are isolated, and the compound (v) is obtained in a one-pot method.
  • the first two steps use a one-pot method to make the compound (iii) and the compound (iv) directly obtain the compound (v) without isolation, which simplifies the operation and reduces the production cost.
  • the preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that: from the compound (V) to the target (i), the compound (vi) is directly subjected to hydrolysis without drying treatment.
  • the desired product thiol derivative (i) is obtained.
  • the L-proline derivative (ii) is protected by a carboxyl group under the catalysis of an organic base to obtain a compound (iii) wherein the ratio of the organic base to the L-proline derivative (ii) is 1 to 4:1. Temperature is - 20 to 30 ° C;
  • the compound (iii) is obtained by directly adding methylsulfonyl chloride for 0.4 to 3 hours without isolation to obtain a compound (iv) wherein the ratio of the methylsulfonyl chloride to the raw material L-proline derivative (ii) is 0.5 to 2 : 1, the reaction temperature is -35 ° C - 10 ° C;
  • the compound (vi) is hydrolyzed in a basic alcohol solution to obtain the desired product thiol derivative (i), and the reaction temperature is -35 to 35° (the alkali solution concentration is 0.1 to 5 mol/L).
  • the preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that -
  • the organic base used in the step A is triethylamine, diisopropylethylamine, pyridine, N,N-dimethylaniline, 4-(N,N-dimethylamino)pyridine, tri-n-propylamine or tri-n-butyl amine;
  • the preparation method of the peronic drug branched-chain intermediate-monothiol derivative characterized in that - the aprotic solvent in step D is hydrazine, hydrazine-dimethylformamide, hydrazine, hydrazine-dimethyl methoxide Acetylamine, acetonitrile, dimethyl sulfoxide or pyridine.
  • the alkaline solution in the crucible is sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium ethoxide, sodium methoxide in methanol or ethanol.
  • the beneficial effects of the present invention are as follows: A method for preparing a peronic drug branched-chain intermediate-thiol derivative is provided, and the first two steps of the preparation method adopt a one-pot method to make the compound (iii) and the compound (iv) need not be used. Separation, direct compound (v), simplifies operation and reduces production costs. At the same time, by changing the process route, the product is easier to purify and the yield is improved. Compared with the prior patent literature, the invention has simple method, the intermediate does not need to be separated, the yield is high, the operation is easy, and the method is suitable for large-scale production. detailed description

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

A preparation method of thiol derivative as side chain intermediate for synthesis of carbapenem derivative. The method is starting with trans-4-hydroxy-L-proline derivative as starting material, following by one-pot method that 2-carbonyl group is protected, 4-hydroxy is protected and 2-postion is substituted to obtain 2-amide proline derivative, then 4-postion is substituted and 4-postion is hydrolyzed in the presence of base to obtain thiol side chain derivative as important intermediate for Meropenem. The present method is simple, without separating intermediates, with high yield and easy to operate and has advantages over the prior patent methods. It is suitable for industrial production.

Description

一种培南类药物支链中间体一一硫醇衍生物的制备方法 技术领域  Preparation method of perampanoid branched-chain intermediate-monothiol derivative

本发明涉及有机化学和药物化学领域, 具体而言, 本发明涉及一种培南 类药物支链中间体——硫醇衍生物的制备方法。 背景技术  The present invention relates to the field of organic chemistry and medicinal chemistry, and in particular, to a method for preparing a thiol derivative of a medicinal branched intermediate of piran. Background technique

培南(碳青霉烯)类药物如亚胺培南、 美罗培南和比亚培南对许多耐药 菌有良好的抗菌作用, 尤其是对 B型酶具有相当强的抑制作用, 是一系列独 特的抑制 内酰胺酶的抑制剂。 (2S, 4S) -取代氨基甲酰基 -4-巯基- 1- (N - 取代) 吡咯垸 (i ) 是培南类药物如美罗培南的重要支链中间体。

Figure imgf000003_0001
Peron (carbampenal) drugs such as imipenem, meropenem and biapenem have good antibacterial activity against many resistant bacteria, especially for B-type enzymes. A unique inhibitor of lactamase inhibition. (2S, 4S)-Substituted carbamoyl-4-mercapto- 1-(N-substituted) pyrrolizole (i) is an important branched intermediate of piranol drugs such as meropenem.
Figure imgf000003_0001

其中, 是低级垸氧基羰基、 卤代垸氧基羰基、 含芳香径的垸氧基羰基 和三垸基硅基, R4、 R5表示相同或不同的含 d-Cs个碳原子的院基、 含 C3-C4 个碳原子的烯烃基、 含 -(:3个碳的烃基取代的芳香基。 Among them, a lower decyloxycarbonyl group, a halogenated decyloxycarbonyl group, a fluorenyloxycarbonyl group having a aromatic diameter, and a trimethylsilyl group, and R 4 and R 5 represent the same or different hospitals containing d-Cs carbon atoms. a olefin group having a C 3 - C 4 carbon atom, a aryl group containing a - ( 3 hydrocarbon group substituted).

^可以是叔丁氧基羰基、 2, 2, 2-三氯乙氧基羰基, 2-溴乙氧基羰基、 邻 硝基苯甲氧基羰基、对硝基苯甲氧基羰基、三甲基硅基、叔丁基二甲基硅基; R2可以是乙氧基羰基、 叔丁氧基羰基、 异丙氧基羰基、 甲磺酰基、 对甲苯磺 酰基。 ^ can be tert-butoxycarbonyl, 2, 2, 2-trichloroethoxycarbonyl, 2-bromoethoxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, trimethyl A silyl group or a tert-butyldimethylsilyl group; and R 2 may be an ethoxycarbonyl group, a tert-butoxycarbonyl group, an isopropoxycarbonyl group, a methanesulfonyl group or a p-toluenesulfonyl group.

R4, R5可以相同或不同包括甲基、 乙基、 正丙基、 异丙基、 正丁基、 叔丁 基、 丙烯基、 丁烯基、 苯基、 取代苯基、 吡啶基、 2-吡啶甲基、 3-吡啶甲基、 4-吡啶甲基。 R 4 and R 5 may be the same or different and include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, propenyl, butenyl, phenyl, substituted phenyl, pyridyl, 2 Pyridinemethyl, 3-pyridylmethyl, 4-pyridylmethyl.

sumitomo pharmaceuticals Co. , Ltd报道了两条化合物 (i ) 的合成路 线 [Makoto S觸 gawa, β -lactam compounds [P] , US4943569, 1990-7-24] 。 第一种方法是以 t ns-4-羟基- L-脯胺酸为原料,经吡咯环上的氨基保护, 2 位羧基保护成酯, 4位羟基取代得巯化物, 然后 2位再经水解得羧酸, 酰胺 化, 4位水解共 6步反应得化合物 (i ), 其反应路线如下式 1 :

Figure imgf000003_0002
Figure imgf000004_0001
另一种方法是以 trans- 4-羟基 -L-脯胺酸为原料, 经吡咯环上的氨基保 护, 2位羧基直接与仲胺反应得到酰胺,再通过 4位取代,水解得化合物(i ), 其合成路线如下式 2: Sumitomo pharmaceuticals Co., Ltd reported the synthetic route of two compounds (i) [Makoto S-touch gawa, β-lactam compounds [P], US 4943569, 1990-7-24]. The first method is to use t ns-4-hydroxy-L-proline as the raw material, protected by the amino group on the pyrrole ring, the 2-position carboxyl group is protected to form an ester, the 4-position hydroxyl group is substituted to obtain a vapor, and then the second position is hydrolyzed. The carboxylic acid, the amidation, and the 4-position hydrolysis are carried out in a total of 6 steps to obtain the compound (i), and the reaction route is as follows:
Figure imgf000003_0002
Figure imgf000004_0001
Another method is to use trans- 4-hydroxy-L-proline as a raw material, protected by an amino group on a pyrrole ring, and the 2-position carboxyl group is directly reacted with a secondary amine to obtain an amide, and then substituted at the 4-position to obtain a compound (i). ), its synthetic route is as follows:

Figure imgf000004_0002
式 2
Figure imgf000004_0002
Equation 2

专利 W09902513 提到另为一条路线是以氨基已保护得 trans- 4-羟基 -L-脯胺 酸为原料, 经 2位羧基、 4位羟基保护, 关环, 开环得到化合物 (i ), 其合 成路线如下式 3: Patent W09902513 mentions another route which uses amino-protected trans-4-hydroxy-L-proline as a raw material, is protected by a 2-carboxyl group, a 4-hydroxyl group, is ring-closed, and is ring-opened to obtain a compound (i). The synthetic route is as follows:

Figure imgf000004_0003
Figure imgf000004_0003

式 3 发明内容  Formula 3 Summary of the Invention

本发明的目的在于提供一种培南类药物支链中间体一一硫醇衍生物的 制备方法, 该制备方法的合成路线如式 4:

Figure imgf000005_0001
The object of the present invention is to provide a preparation method of a perylene-based drug branched-chain intermediate-thiol derivative, and the synthetic route of the preparation method is as shown in formula 4:
Figure imgf000005_0001

(v)  (v)

(·)  (·)

本发明方法的技术方案是: The technical solution of the method of the invention is:

^式  ^

一种培南类药物支链中间体一一硫 4醇衍生物的制备方法, 其特征在于该 方法包括下述步骤:  A method for preparing a peronal drug branched-chain intermediate monothiol alcohol derivative, characterized in that the method comprises the following steps:

A)、 以 L-脯胺酸衍生物(ii)为原料,在有机碱存在下经羧基保护得到化 合物(iii):  A), using L-proline derivative (ii) as a raw material, and protecting the compound (iii) by a carboxyl group in the presence of an organic base:

VN COORi

Figure imgf000005_0002
VN COORi
Figure imgf000005_0002

B)、 化合物 (iii) 与甲基磺酰氯反应得到化合物 (iv):

Figure imgf000005_0003
B), compound (iii) is reacted with methylsulfonyl chloride to give compound (iv):
Figure imgf000005_0003

0、 将化合物 (iv) 与盐酸二甲胺反应得到化合物 (V)  0. The compound (iv) is reacted with dimethylamine hydrochloride to obtain a compound (V)

Figure imgf000005_0004
Figure imgf000005_0004

D)、 将化合物 (v) 与硫代乙酸钾或硫代乙酸反应得到化合物 (vi)  D), reacting compound (v) with potassium thioacetate or thioacetic acid to obtain compound (vi)

Figure imgf000005_0005
Figure imgf000005_0005

E)、 将化合物(vi)碱性条件下水解得到培南类药物支链中间体的硫醇 衍生物 (i)。

Figure imgf000006_0001
其中: 表示酰基化合物。 E), the compound (vi) is hydrolyzed under basic conditions to obtain a thiol derivative (i) of a perindanic branched intermediate.
Figure imgf000006_0001
Wherein: represents an acyl compound.

所述的培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于:  The preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that:

从 L-脯胺酸衍生物(ii)到化合物(V), 化合物(iii)和化合物(iv) 是不经分离的, 直接一锅法得到化合物(v)。 前两步采用一锅法使得化合物 (iii), 化合物 (iv) 无需分离, 直接得到化合物 (v), 简化了操作, 降低 了生产成本。  From the L-proline derivative (ii) to the compound (V), the compound (iii) and the compound (iv) are isolated, and the compound (v) is obtained in a one-pot method. The first two steps use a one-pot method to make the compound (iii) and the compound (iv) directly obtain the compound (v) without isolation, which simplifies the operation and reduces the production cost.

所述的培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于: 从化合物 (V) 到目标物 (i), 其化合物 (vi) 不经干燥处理, 直接进 行水解得到目标产物硫醇衍生物 (i)。  The preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that: from the compound (V) to the target (i), the compound (vi) is directly subjected to hydrolysis without drying treatment. The desired product thiol derivative (i) is obtained.

所述的培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于:  The preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that:

L -脯胺酸衍生物(ii)在有机碱的催化下经羧基保护得到化合物(iii), 其中有机碱与 L-脯胺酸衍生物 (ii) 的配比为 1〜4: 1, 反应温度为- 20〜 30°C;  The L-proline derivative (ii) is protected by a carboxyl group under the catalysis of an organic base to obtain a compound (iii) wherein the ratio of the organic base to the L-proline derivative (ii) is 1 to 4:1. Temperature is - 20 to 30 ° C;

得到化合物(iii) 不经分离, 直接加入甲基磺酰氯反应 0.4〜3小时得 到化合物(iv),其中甲基磺酰氯与原料 L-脯胺酸衍生物(ii)的配比为 0.5〜 2: 1, 反应温度为 -35°C- 10°C;  The compound (iii) is obtained by directly adding methylsulfonyl chloride for 0.4 to 3 hours without isolation to obtain a compound (iv) wherein the ratio of the methylsulfonyl chloride to the raw material L-proline derivative (ii) is 0.5 to 2 : 1, the reaction temperature is -35 ° C - 10 ° C;

化合物 (iv) 加盐酸二甲胺反应 0.5〜6小时得到化合物 (V), 其中盐 酸二甲胺与原料 L-脯胺酸衍生物(ii)的配比为 0.5〜2: 1, 反应温度在- 35 °C- 10°C;  Compound (iv) is reacted with dimethylamine hydrochloride for 0.5 to 6 hours to obtain compound (V), wherein the ratio of dimethylamine hydrochloride to the starting material L-proline derivative (ii) is 0.5 to 2: 1, and the reaction temperature is - 35 °C - 10 °C;

化合物 (V) 与硫代乙酸钾或硫代乙酸在非质子性溶剂中, 25〜60°C反 应 10〜25小时得到化合物(vi); 其中硫代乙酸钾或硫代乙酸与化合物(V) 的配比为 0.5〜3: 1  Compound (V) is reacted with potassium thioacetate or thioacetic acid in an aprotic solvent at 25 to 60 ° C for 10 to 25 hours to obtain compound (vi); wherein potassium thioacetate or thioacetic acid and compound (V) The ratio is 0.5~3: 1

化合物(vi)在碱性醇溶液中水解反应,得到目标产物硫醇衍生物(i), 反应温度- 35〜35° ( , 碱溶液浓度 0. l〜5mol/L。  The compound (vi) is hydrolyzed in a basic alcohol solution to obtain the desired product thiol derivative (i), and the reaction temperature is -35 to 35° (the alkali solution concentration is 0.1 to 5 mol/L).

所述的培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于- 步骤 A中用的有机碱是三乙胺, 二异丙基乙胺, 吡啶, N, N-二甲基苯 胺, 4_ (N, N-二甲基氨基) 吡啶, 三正丙胺或三正丁胺; The preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that - The organic base used in the step A is triethylamine, diisopropylethylamine, pyridine, N,N-dimethylaniline, 4-(N,N-dimethylamino)pyridine, tri-n-propylamine or tri-n-butyl amine;

所述的培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于- 步骤 D中的非质子性溶剂是 Ν, Ν-二甲基甲酰胺、 Ν,Ν-二甲基乙酰胺、 乙 腈、 二甲亚砜或吡啶。  The preparation method of the peronic drug branched-chain intermediate-monothiol derivative, characterized in that - the aprotic solvent in step D is hydrazine, hydrazine-dimethylformamide, hydrazine, hydrazine-dimethyl methoxide Acetylamine, acetonitrile, dimethyl sulfoxide or pyridine.

所述的培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于:  The preparation method of the peronic drug branched-chain intermediate-monothiol derivative is characterized in that:

步骤 Ε中的碱性溶液是氢氧化钠、氢氧化钾、碳酸钠、碳酸钾、 乙醇钠、 甲醇钠的甲醇溶液或乙醇溶液。 本发明的有益效果是; 提供了一种培南类药物支链中间体一一硫醇衍生 物的制备方法, 该制备方法前两步采用一锅煮的方法使得化合物(iii )、 化 合物(iv)无需分离, 直接得到化合物(v), 简化了操作, 降低了生产成本。 同时, 通过改变工艺路线, 产品更易提纯, 提高了收率。 本发明较已有专利 文献报导的方法简单, 中间体不需分离, 收率高, 易于操作, 适合大规模生 产。 具体实施方式  Step The alkaline solution in the crucible is sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium ethoxide, sodium methoxide in methanol or ethanol. The beneficial effects of the present invention are as follows: A method for preparing a peronic drug branched-chain intermediate-thiol derivative is provided, and the first two steps of the preparation method adopt a one-pot method to make the compound (iii) and the compound (iv) need not be used. Separation, direct compound (v), simplifies operation and reduces production costs. At the same time, by changing the process route, the product is easier to purify and the yield is improved. Compared with the prior patent literature, the invention has simple method, the intermediate does not need to be separated, the yield is high, the operation is easy, and the method is suitable for large-scale production. detailed description

. 下面通过具体实施例来进一步说明本发明。  The invention is further illustrated by the following examples.

实施例 1 (2S, 4R) 1- (对硝基苄氧基羰基) -2- (N, N-二甲基氨基 酰基) -4-甲磺酸基吡咯垸的制备  Example 1 Preparation of (2S, 4R) 1-(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoacyl)-4-methanesulfonylpyrrole

在 500ml反应瓶中加入二氯甲烷(300ml ), 搅拌, 加入 N-对硝基苄氧基 羰基- 4- S-羟基脯氨酸(20g, 64. 5mmol ),冷却至 - 20°C,加入三乙胺(19. 5g, 193mmol ), 搅拌 5分钟, 滴加氯甲酸异丙酯 (8. 2g, 67. 2mmol ), 约滴加 1 小时, 反应 5小时后, 继续降温至 -35°C, 然后分批加入甲磺酰氯 (14. 7g, 128mmol ),加完后继续搅拌 3小时,然后加入盐酸二甲胺(5. 3g, 64. 5mmol ), 搅拌反应 6小时后加入水 120ml, 萃取分层, 有机层用无水硫酸钠干燥, 减 压下蒸除溶剂, 然后加入乙酸乙酯溶解, 滴加石油醚析出固体, 过滤, 烘千 得中间体 (2S, 4R) 1- (对硝基苄氧基羰基) -2- (N, N-二甲基氨基酰基) - 4 -甲磺酸基吡咯垸 (21. lg, 78. 7% )。  Add dichloromethane (300 ml) to a 500 ml reaction flask, stir, add N-p-nitrobenzyloxycarbonyl-4-S-hydroxyproline (20 g, 64.5 mmol), cool to -20 ° C, add Triethylamine (19.5 g, 193 mmol), stirred for 5 minutes, isopropyl chloroformate (8.2 g, 67. 2 mmol) was added dropwise, about 1 hour dropwise, and after 5 hours of reaction, the temperature was further lowered to -35 ° C. Then, methanesulfonyl chloride (14.7 g, 128 mmol) was added in portions, and stirring was continued for 3 hours, then dimethylamine hydrochloride (5.3 g, 64. 5 mmol) was added, and the reaction was stirred for 6 hours, then 120 ml of water was added, and extracted. The organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure, then ethyl acetate was dissolved, and the solid was precipitated with petroleum ether, filtered, and dried to obtain intermediate (2S, 4R) 1- (Benzyloxycarbonyl)-2-(N,N-dimethylaminoacyl)-4-carboxysulfonylpyrrole (21. lg, 78.7%).

实施例 2 (2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲基氨基 酰基) -4 -巯基吡咯烷的制备 Example 2 (2S, 4S) 1-(p-Nitrobenzyloxycarbonyl)-2-(N,N-dimethylamino Preparation of acyl)-1,4-mercaptopyrrolidine

在 250ml反应瓶中加入 DMF ( 150ml ),(2S, 4R) 1_对硝基苄氧基羰基- 2- (N, N-二甲基氨基酰基) - 4-S -甲磺酸基吡咯垸 (15. 0g, 36iranol ), 搅拌 溶解, 加入硫代乙酸钾 (4. 3g, 37. 7mmol) , 25°C下反应 10小时, 然后快速 倒入 1000ml冰水中, 搅拌析出固体, 过滤得湿品。  In a 250 ml reaction flask was added DMF (150 ml), (2S, 4R) 1_p-nitrobenzyloxycarbonyl-2-(N,N-dimethylaminoacyl)-4-S-methanesulfonate (15. 0g, 36iranol), stirred and dissolved, added potassium thioacetate (4.3 g, 37.7 mmol), reacted at 25 ° C for 10 hours, then quickly poured into 1000 ml of ice water, stirred to precipitate a solid, filtered to obtain a wet product .

将得到的湿品加入 100ml二氯甲烷中, 搅拌, 然后加入 0. lmol/L氢氧 化钠甲醇溶液 15ml, 5 °C下搅拌反应 5分钟,然后加入稀盐酸调 PH值至 2. 5〜3 左右, 分层, 有机层减压下蒸干, 加入甲醇溶解, 然后加入石油醚析出固体, 过滤, 烘干得 (2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲基氨基酰 基) -4 -巯基吡咯垸 ( 12. 2g, 95%)。  0〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3〜3~3~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Left and right, layered, the organic layer was evaporated to dryness under reduced pressure, dissolved in methanol, and then solidified with petroleum ether, filtered and dried to give (2S, 4S) 1- (p-nitrobenzyloxycarbonyl) -2- (N , N-Dimethylaminoacyl)-4-indolylpyrrole (12. 2g, 95%).

实施例 3 (2S, 4R) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰基) -4-甲磺酸基吡咯垸的制备  Example 3 Preparation of (2S, 4R) 1-(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoyl)-4-methanesulfonylpyrrole

在烧瓶中加入二氯甲烷(250ml ),搅拌,加入 N-对硝基苄氧基羰基- 4 - S- 羟基脯氨酸 (16. 2g, 52匪 ol ), 冷却至 5°C, 加入二异丙基乙胺 (6. 4g, 55函 ol ), 搅拌 5〜10分钟, 滴加氯甲酸乙酯 5. 7g, 52. 8画1 ), 约滴加 1 小时, 反应 2小时后滴加甲磺酰氯 (6g, 52. 2mmol ), 加完后继续搅拌 1小 时,然后加入盐酸二甲胺(8. 2g, lOOmmol ),搅拌反应 2小时后加入水 100ml, 萃取分层, 有机层用无水硫酸钠干燥, 减压下蒸除溶剂, 然后加入乙醇搅拌 溶解, 滴加石油醚析出固体, 过滤, 烘干得中间体 ((2S, 4R) 1 (对硝基 苄氧基羰基) -2- (N, N-二甲氨基酰基) -4-甲磺酸基吡咯垸(17. 8g, 82%)。  Add dichloromethane (250 ml) to the flask, stir, add N-p-nitrobenzyloxycarbonyl-4-S-hydroxyproline (16.2 g, 52 匪ol), cool to 5 ° C, add two Isopropylethylamine (6.4 g, 55 ol), stirring for 5 to 10 minutes, dropwise addition of ethyl chloroformate 5. 7 g, 52. 8 paintings 1 ), about 1 hour dropwise, 2 hours after the reaction, adding dropwise Methanesulfonyl chloride (6 g, 52.2 mmol), stirring was continued for 1 hour after the addition, then dimethylamine hydrochloride (8.2 g, 100 mmol) was added, and the reaction was stirred for 2 hours, then 100 ml of water was added, and the layers were separated, and the organic layer was used. Drying with sodium sulfate, distilling off the solvent under reduced pressure, then adding ethanol, stirring and dissolving, adding petroleum ether to precipitate a solid, filtering, and drying to obtain intermediate ((2S, 4R) 1 (p-nitrobenzyloxycarbonyl) -2 - (N, N-Dimethylaminoacyl)-4-methylsulfonylpyrrole (17. 8 g, 82%).

实施例 4 (2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰 基) -4-巯基吡咯烷的制备  Example 4 Preparation of (2S, 4S) 1-(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoyl)-4-indolylpyrrolidine

在 250ml反应瓶中加入 DMF ( 120ml ), (2S, 4R) 1 -对硝基苄氧基羰基- (2-N, N-二甲氨基酰基) -4-甲磺酸基吡咯垸(13. 3g, 31. 9mmol ), 搅拌溶 解, 加入硫代乙酸 (4. 85g, 63. 8mmol ), 60°C下反应 25小时, 然后快速倒 入 1000ml冰水中, 搅拌析出固体, 过滤得湿品。  In a 250 ml reaction flask was added DMF (120 ml), (2S, 4R) 1-p-nitrobenzyloxycarbonyl-(2-N,N-dimethylaminoacyl)-4-methanesulfonylpyrrole (13. 3 g, 31. 9 mmol), stirred and dissolved, added thioacetic acid (4.85 g, 63.8 mmol), and reacted at 60 ° C for 25 hours, then quickly poured into 1000 ml of ice water, and the precipitated solid was stirred and filtered to obtain a wet product.

将得到的湿品加入 100ml二氯甲垸中, 搅拌, 然后加入 5mol/L氢氧化 钾乙醇溶液 30ml, 一 25°C下搅拌反应一小时, 然后加入稀盐酸调 PH值至 2. 5〜3左右, 分层, 有机层减压下蒸千, 加入甲醇溶解, 然后加入石油醚析 出固体, 过滤, 烘干得 (2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲 氨基酰基) -4-巯基吡咯垸 (9. 6g, 85%)。  0〜3〜3〜3〜3~3~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Left and right, layered, the organic layer is steamed under reduced pressure, dissolved in methanol, and then added with petroleum ether to precipitate a solid, which is filtered and dried to give (2S, 4S) 1-(p-nitrobenzyloxycarbonyl)-2-(N , N-dimethylamino acyl)-4-mercaptopyrrole (9. 6g, 85%).

实施例 5 (2S, 4R) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰 基) -4-甲磺酸基吡咯垸的制备 Example 5 (2S, 4R) 1-(p-Nitrobenzyloxycarbonyl)-2-(N,N-dimethylamino) Preparation of -4-methylsulfonylpyrrole

在 500ml反应瓶中加入二氯甲烷(300ml), 搅拌, 加入 N-对硝基苄氧基 羰基- 4-S-羟基脯氨酸(20g, 64.5腿 ol), 30°C加入吡啶(20.3g, 257mmol), 搅拌^ 10钟, 滴加氯甲酸叔丁酯(9.2g, 67.6mmol), 0.5〜1小时滴加完毕, 保持 30°C下反应 1小时后, 将温度降至 10°C, 然后滴加甲磺酰氯 (4. lg, 35.5mmol), 加完后继续搅拌 0.4 小时, 然后加入盐酸二甲胺 (2.7g, 33. lmmol), 搅泮反应 0.5小时后加入水 120ml, 萃取分层, 有机层用无水硫 酸钠干燥,减压下蒸除溶剂,然后加入乙酸乙酯溶解,滴加石油醚析出固体, 过滤, 烘干得中间体 (2S, 4R) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨 基酰基) - 4-甲磺酸基吡咯烷 (15.0g, 56%)。  Dichloromethane (300 ml) was added to a 500 ml reaction flask, stirred, and N-p-nitrobenzyloxycarbonyl-4-S-hydroxyproline (20 g, 64.5 leg ol) was added, and pyridine (20.3 g) was added at 30 °C. , 257 mmol), stirred for 10 minutes, t-butyl chloroformate (9.2 g, 67.6 mmol) was added dropwise, and the addition was completed in 0.5 to 1 hour. After maintaining the reaction at 30 ° C for 1 hour, the temperature was lowered to 10 ° C. Then, methanesulfonyl chloride (4. lg, 35.5 mmol) was added dropwise. After the addition was completed, stirring was continued for 0.4 hours, then dimethylamine hydrochloride (2.7 g, 33. lmmol) was added, and the reaction was stirred for 0.5 hour, then 120 ml of water was added, and the extract was extracted. The organic layer is dried over anhydrous sodium sulfate, and the solvent is evaporated under reduced pressure, then ethyl acetate is dissolved, and the solid is precipitated with petroleum ether, filtered, and dried to give intermediate (2S, 4R) 1- Benzyloxycarbonyl)-2-(N,N-dimethylaminoacyl)-4-methanesulfonylpyrrolidine (15.0 g, 56%).

实施例 6 (2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰 基) -4-巯基吡咯垸的制备  Example 6 Preparation of (2S, 4S) 1-(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoyl)-4-mercaptopyrrole

在反应瓶中加入 DMSO (75ml), (2S, 4R) 1_ (对硝基苄氧基羰基) - 2- (N, N-二甲氨基酰基) -4-甲磺酸基吡咯垸(8. lg, 19.5mmol), 搅拌溶解, 加入硫代乙酸钾(6.8g, 58.7ranol), 40°C下反应 21小时,然后快速倒入 600ml 冰水中, 搅拌析出固体, 过滤得湿品。  In the reaction flask was added DMSO (75 ml), (2S, 4R) 1_(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoacyl)-4-methanesulfonylpyrrole (8. Lg, 19.5 mmol), stirred and dissolved, added potassium thioacetate (6.8 g, 58.7 ranol), and reacted at 40 ° C for 21 hours, then quickly poured into 600 ml of ice water, stirred to precipitate a solid, and filtered to obtain a wet product.

将得到的湿品加入 80ml二氯甲垸中, 搅拌, 然后加入 2mol/L乙醇钠的 乙醇溶液 30ml, 35°C下搅拌反应 50分钟, 然后加入稀盐酸调 PH值至 2.5~3 左右, 分层, 有机层减压下蒸干, 加入甲醇溶解, 然后加入石油醚析出固体, 过滤, 烘干得(2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰基) -4-巯基吡咯垸 (3.9g, 56.6%)。  Add the obtained wet product to 80 ml of dichloromethane, stir, then add 30 ml of 2 mol/L sodium ethoxide in ethanol, stir the reaction at 35 ° C for 50 minutes, then add dilute hydrochloric acid to adjust the pH to 2.5~3, The organic layer is evaporated to dryness under reduced pressure, dissolved in methanol, and then petroleum ether is added to precipitate a solid, which is filtered and dried to give (2S, 4S) 1-(p-nitrobenzyloxycarbonyl)-2-(N, N- Dimethylamino)-4-indolylpyrrole (3.9 g, 56.6%).

实施例 7 (2S, 4R) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰 基) -4-甲磺酸基吡咯垸的制备  Example 7 Preparation of (2S, 4R) 1-(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoyl)-4-methylsulfonylpyrrole

在 500ml反应瓶中加入二氯甲垸(300ml), 搅拌, 加入 N-对硝基苄氧基 羰基 -4- S-羟基脯氨酸 (20g, 64.5mmol), _5°C加入二异丙基乙胺 (14.9g, 129讓 ol), 搅拌 5〜: L0钟, 滴加氯甲酸乙酯 (7. lg, 65.5画1), 0.5〜1小时 滴加完毕, 反应 3小时后滴加甲磺酰氯 (9.9, 86.8mmol), 加完后继续搅拌 1.5〜2小时, 然后加入盐酸二甲胺(5.4g, 66mmol), 搅拌反应 4小时后加入 水 120ml, 萃取分层, 有机层用无水硫酸钠干燥, 减压下蒸除溶剂, 然后加 入乙酸乙酯溶解, 滴加石油醚析出固体, 过滤, 烘干得中间体 (2S, 4R) 1 - (对硝基苄氧基羰基)-2- (N, N-二甲氨基酰基)-4-甲磺酸基吡咯垸(22.5g, 实施例 8 (2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰 基) -4-巯基吡咯烷的制备 Add methylene chloride (300 ml) to a 500 ml reaction flask, stir, add N-p-nitrobenzyloxycarbonyl-4-S-hydroxyproline (20 g, 64.5 mmol), add isopropyl at _5 °C Ethylamine (14.9g, 129 let ol), stir 5~: L0 clock, add ethyl chloroformate (7. lg, 65.5 draw 1), add 0.5~1 hour, add methyl sulfonate after 3 hours of reaction Acid chloride (9.9, 86.8 mmol), stirring was continued for 1.5 to 2 hours after the addition, then dimethylamine hydrochloride (5.4 g, 66 mmol) was added, and the reaction was stirred for 4 hours, then 120 ml of water was added, and the layers were separated, and the organic layer was treated with anhydrous sulfuric acid. Dry the sodium, distill the solvent under reduced pressure, then dissolve with ethyl acetate, add petroleum ether to precipitate a solid, filter, and dry to give intermediate (2S, 4R) 1 - (p-nitrobenzyloxycarbonyl)-2- (N, N-dimethylamino)-4-methanesulfonate pyrrolidine (22.5 g, Example 8 Preparation of (2S, 4S) 1-(p-Nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoyl)-4-indolylpyrrolidine

在反应瓶中加入乙腈( 100ml ), (2S, 4R) 1- (对硝基苄氧基羰基) - 2 - (N, N-二甲氨基酰基) -4-甲磺酸基吡咯垸(15g, 36mmol ), 搅拌溶解, 加 入硫代乙酸钾(2. lg, 18. 4mmol ), 35°C下反应 14小时,然后快速倒入 800ml 冰水中, 搅拌析出固体, 过滤得湿品。  In the reaction flask was added acetonitrile (100 ml), (2S, 4R) 1-(p-nitrobenzyloxycarbonyl)-2-(N,N-dimethylaminoacyl)-4-methanesulfonylpyrrole (15 g) , 36 mmol), stirred and dissolved, added potassium thioacetate (2. lg, 18. 4 mmol), and reacted at 35 ° C for 14 hours, then quickly poured into 800 ml of ice water, and the precipitated solid was stirred and filtered to obtain a wet product.

将得到的湿品加入 100ml二氯甲垸中, 搅拌, 然后加入 0. 2mol/L碳酸 钠乙醇溶液 20ml, -35 "C下搅拌反应 20分钟,然后加入稀盐酸调 PH值至 2. 5〜3 左右, 分层, 有机层减压下蒸干, 加入甲醇溶解, 然后加入石油醚析出固体, 过滤, 烘干得(2S, 4S) 1- (对硝基苄氧基羰基) -2- (N, N-二甲氨基酰基) -4-巯基吡咯垸 (9. 3g, 73%)。  5〜 The pH is adjusted to 2. 5~ Add the diluted hydrochloric acid to adjust the pH value to 2. 5~ 3, layering, the organic layer is evaporated to dryness under reduced pressure, dissolved in methanol, then added to petroleum ether to precipitate solids, filtered, and dried to give (2S, 4S) 1-(p-nitrobenzyloxycarbonyl)-2- ( N, N-dimethylamino acyl)-4-mercaptopyrrole (9.3 g, 73%).

Claims

权 利 要 求 Rights request 1、 一种培南类药物支链中间体一一硫醇衍生物的制备方法, 其特征在 于该方法包括下述步骤:  A method for preparing a perindyl-based drug branched-chain intermediate-thiol derivative, characterized in that the method comprises the steps of: A)、 以 L-脯胺酸衍生物(ii)为原料,在有机碱存在下经羧基保护得到化 合物(iii):
Figure imgf000011_0001
A), using L-proline derivative (ii) as a raw material, and protecting the compound (iii) by a carboxyl group in the presence of an organic base:
Figure imgf000011_0001
B)、 化合物 (iii) 与甲基磺酰氯反应得到化合物 (iv):
Figure imgf000011_0002
B), compound (iii) is reacted with methylsulfonyl chloride to give compound (iv):
Figure imgf000011_0002
C)、 将化合物 (iv) 与盐酸二甲胺反应得到化合物 (V)
Figure imgf000011_0003
C), reacting compound (iv) with dimethylamine hydrochloride to obtain compound (V)
Figure imgf000011_0003
D)、 将化合物 (v) 与硫代乙酸钾或硫代乙酸反应得到化合物 (vi)  D), reacting compound (v) with potassium thioacetate or thioacetic acid to obtain compound (vi)
Figure imgf000011_0004
Figure imgf000011_0004
E)、 将化合物(vi)碱性条件下水解得到培南类药物支链中间体的硫醇 物 (i)。  E), the compound (vi) is hydrolyzed under basic conditions to obtain a mercaptan (i) of a perindanic branched intermediate.
Figure imgf000011_0005
其中: Ri表示酰基化合物。
Figure imgf000011_0005
Wherein: Ri represents an acyl compound.
2、 根据权利要求 1所述的培南类药物支链中间体一一硫醇衍生物的制 备方法, 其特征在于:  The method for preparing a peronal drug branched-chain intermediate-monothiol derivative according to claim 1, which is characterized in that: 从 L-脯胺酸衍生物(ii) 到化合物(v), 化合物(iii)和化合物(iv) 是不经分离的, 直接一锅法得到化合物 (v)。 From L-proline derivative (ii) to compound (v), compound (iii) and compound (iv) The compound (v) is obtained in a one-pot method without isolation. 3、 根据权利要求 1所述的培南类药物支链中间体一一硫醇衍生物的制 备方法, 其特征在于: 从化合物 (V) 到目标物 (i), 其化合物 (vi) 不经 干燥处理, 直接进行水解得到目标产物硫醇衍生物 (i)。  The method for preparing a peronic drug branched-chain intermediate-monothiol derivative according to claim 1, wherein: from the compound (V) to the target (i), the compound (vi) is not The drying treatment is carried out directly to obtain the desired product thiol derivative (i). 4、 根据权利要求 1或 2或 3所述的培南类药物支链中间体一一硫醇衍 生物的制备方法, 其特征在于:  The method for preparing a peronal drug branched-chain intermediate-monothiol derivative according to claim 1 or 2 or 3, which is characterized in that: L-脯胺酸衍生物(ii)在有机碱的催化下经羧基保护得到化合物(iii), 其中有机碱与 L-脯胺酸衍生物 (ii) 的配比为 1〜4: 1, 反应温度为 -20〜 30°C;  The L-proline derivative (ii) is protected by a carboxyl group under the catalysis of an organic base to obtain a compound (iii) wherein the ratio of the organic base to the L-proline derivative (ii) is 1 to 4:1. The temperature is -20~ 30 °C; 得到化合物 (iii)不经分离, 直接加入甲基磺酰氯反应 0.4〜3小时得 到化合物(iv),其中甲基磺 氯与原料 L-脯胺酸衍生物(ii)的配比为 0.5〜 2: 1, 反应温度为 -35°C-10°C;  Obtaining the compound (iii) without isolation, directly adding methylsulfonyl chloride for 0.4 to 3 hours to obtain a compound (iv) wherein the ratio of the methylsulfonate to the raw material L-proline derivative (ii) is 0.5 to 2 : 1, the reaction temperature is -35 ° C -10 ° C; 化合物 (iv) 加盐酸二甲胺反应 0.5〜6小时得到化合物 (v), 其中盐 酸二甲胺与原料 L-脯胺酸衍生物(ii)的配比为 0.5〜2: 1, 反应温度在 -35 °C-10°C;  Compound (iv) is reacted with dimethylamine hydrochloride for 0.5 to 6 hours to obtain compound (v), wherein the ratio of dimethylamine hydrochloride to the starting material L-proline derivative (ii) is 0.5 to 2: 1, and the reaction temperature is -35 °C - 10 °C; 化合物 (v) 与硫代乙酸钾或硫代乙酸在非质子性溶剂中, 25〜60°C反 应 10〜25小时得到化合物(vi); 其中硫代乙酸钾或硫代乙酸与化合物(V) 的配比为 0.5〜3: 1  Compound (v) is reacted with potassium thioacetate or thioacetic acid in an aprotic solvent at 25 to 60 ° C for 10 to 25 hours to obtain compound (vi); wherein potassium thioacetate or thioacetic acid and compound (V) The ratio is 0.5~3: 1 化合物(vi)在碱性醇溶液中水解反应,得到目标产物硫醇衍生物(i), 反应温度 -35〜35°C, 碱溶液浓度 0· l〜5mol/L。  The compound (vi) is hydrolyzed in a basic alcohol solution to obtain a target product thiol derivative (i), a reaction temperature of -35 to 35 ° C, and an alkali solution concentration of 0·1 to 5 mol/L. 5、 根据权利要求 1或 2或 3或 4所述的培南类药物支链中间体一一硫 醇衍生物的制备方法, 其特征在于:  The method for producing a perylene-based drug branched-chain intermediate-thiol derivative according to claim 1 or 2 or 3 or 4, which is characterized in that: 步骤 A中用的有机碱是三乙胺, 二异丙基乙胺, 吡啶, N, N-二甲基苯 胺, 4- (N, N-二甲基氨基) 吡啶, 三正丙胺或三正丁胺;  The organic base used in the step A is triethylamine, diisopropylethylamine, pyridine, N,N-dimethylaniline, 4-(N,N-dimethylamino)pyridine, tri-n-propylamine or tri-n-butyl Butylamine 6、根据权利要求 1或 2或 3或 4或 5所述的培南类药物支链中间体一一 硫醇衍生物的制备方法, 其特征在于:  The method for producing a perindane-based branched-chain intermediate-thiol derivative according to claim 1 or 2 or 3 or 4 or 5, which is characterized in that: 步骤 D中的非质子性溶剂是 N,N-二甲基甲酰胺、 N,N-二甲基乙酰胺、乙 腈、 二甲亚砜或吡啶。  The aprotic solvent in step D is N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, dimethyl sulfoxide or pyridine. 7、 根据权利要求 1或 2或 3或 4或 5或 6所述的培南类药物支链中间 体一一硫醇衍生物的制备方法, 其特征在于:  The method for producing a perindole-based branched-chain intermediate-thiol derivative according to claim 1 or 2 or 3 or 4 or 5 or 6, which is characterized in that: 步骤 E中的碱性溶液是氢氧化钠、氢氧化钾、碳酸钠、碳酸钾、 乙醇钠、 甲醇钠的乙醇溶液或甲醇溶液。  The alkaline solution in the step E is sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium ethoxide, sodium methoxide in ethanol or methanol.
PCT/CN2008/000814 2007-04-28 2008-04-21 A preparation method of thiol derivative as side chain intermediate for synthesis of carbapenem derivative Ceased WO2008134923A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200710068259.X 2007-04-28
CNA200710068259XA CN101041632A (en) 2007-04-28 2007-04-28 Preparation method of penem drug branched chain intermediate-mercaptan derivative

Publications (1)

Publication Number Publication Date
WO2008134923A1 true WO2008134923A1 (en) 2008-11-13

Family

ID=38807449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/000814 Ceased WO2008134923A1 (en) 2007-04-28 2008-04-21 A preparation method of thiol derivative as side chain intermediate for synthesis of carbapenem derivative

Country Status (2)

Country Link
CN (1) CN101041632A (en)
WO (1) WO2008134923A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012079289A1 (en) * 2010-12-16 2012-06-21 珠海亿邦制药股份有限公司 Amorphous powder and polymorph of carbapenem derivative, preparation method therefor and use thereof
CN105439932B (en) * 2014-08-27 2018-06-29 北大方正集团有限公司 A kind of penem-like pharmaceutical intermediate and preparation method thereof
CN105439933B (en) * 2014-08-27 2017-11-24 北大方正集团有限公司 A kind of preparation method of penem-like pharmaceutical mercaptan side chain
CN114163371B (en) * 2021-12-21 2024-05-14 天津市敬业精细化工有限公司 Meropenem side chain optical isomer, preparation method and application thereof, and meropenem side chain impurity detection method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943569A (en) * 1983-05-09 1990-07-24 Sumitomo Pharmaceuticals Co., Ltd. B-lactam compounds
WO1999002513A1 (en) * 1997-07-09 1999-01-21 Novo Nordisk A/S Preparation of diaryl-benzopyrans

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943569A (en) * 1983-05-09 1990-07-24 Sumitomo Pharmaceuticals Co., Ltd. B-lactam compounds
WO1999002513A1 (en) * 1997-07-09 1999-01-21 Novo Nordisk A/S Preparation of diaryl-benzopyrans

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAKOTO S. ET AL.: "A novel carbapenem antibiotic, SM-7338 structure-activity relationships", THE JOURNAL OF ANTIBIOTICS, vol. 43, no. 5, pages 519 - 532, XP002912928 *

Also Published As

Publication number Publication date
CN101041632A (en) 2007-09-26

Similar Documents

Publication Publication Date Title
EP0570594B1 (en) Hydroxamic acid derivative based on aromatic sulfonamide
US8981105B2 (en) Process of preparing a thrombin specific inhibitor
CN103649055B (en) For the preparation of the method for pyrazole derivatives
CZ293694B6 (en) Pharmaceutical composition containing 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
WO2006019020A1 (en) Substituted ureas
TWI426074B (en) Method for producing 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamide
WO2009129370A1 (en) Cathepsin c inhibitors
WO2001000587A1 (en) Azolylbenzamides and analogues and their use for treating osteoporosis
WO2016181414A1 (en) Process for the synthesis of ivacaftor and related compounds
CN110041333A (en) Bromine structural domain inhibitor compound and application thereof
WO2010121382A1 (en) Process for making indole cyclopropyl amide derivatives
WO2016017711A1 (en) Pyrazole derivative manufacturing method
WO2004108673A2 (en) Inhibitors of papilloma virus
WO2008134923A1 (en) A preparation method of thiol derivative as side chain intermediate for synthesis of carbapenem derivative
WO2000027792A1 (en) Novel compounds and medicinal use thereof
CN104860935A (en) Thiophene or its variant derivatives as hepatitis C virus inhibitor and pharmaceutical use thereof
KR20250007528A (en) 5-Pyridine-1H-indazole compounds, pharmaceutical compositions and applications
TWI887245B (en) Processes and intermediates for producing diazaspiro lactam compounds
KR20010033528A (en) Indole Derivatives Useful A.O. for the Treatment of Osteoporosis
WO2011095125A1 (en) Synthesis methods and purification methods of dasatinib
CN102199132A (en) Method for preparing 2-(2-amino-4-thiazole)-2(Z)-[[(tertbutyloxycarbonyl) methoxyl] imido] acetic acid and salt thereof
JP2001519328A (en) Azetidinone derivatives for the treatment of HCMV infection
WO2007009354A1 (en) Pyrrolidine derivative intermediates,preparation and usage thereof
CN100422170C (en) The preparation method of quinolone carboxylic acid derivative
CN117164582A (en) A kind of protease inhibitor and pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08734005

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08734005

Country of ref document: EP

Kind code of ref document: A1